Here, we examine the potential relevance of JAK2 inhibition in CML by examining the biological effects of a highly selective, orally bioavailable JAK2 inhibitor BMS-911543 alone and in combination with second generation TKIs, including dasatinib (DA), on CD34+ treatment-naïve IM-nonresponder cells. Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.